Literature DB >> 16352433

Immunoreactivity assay for alpha-particle emitting monoclonal antibody constructs.

Anthony S Bonavia1, Michael R McDevitt, Michael J Curcio, David A Scheinberg.   

Abstract

Clinical trials using alpha-particle radiolabeled antibodies require a rapid and reproducible assay of the immunoreactivity of drugs. While live cell assays are typically used to determine the immunoreactive drug fraction, a fixed cell assay may replace the traditional live cell assay and offer the advantages of rapidity, easy availability and consistency for qualifying drugs for preclinical or clinical studies. We have identified optimal cell fixation and immunoreactivity assay conditions and have validated them by performing the fixed-cell assay in clinical trials.

Mesh：

Substances：

Year:  2005        PMID： 16352433     DOI： 10.1016/j.apradiso.2005.11.004

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  4 in total

1.  Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier.

Authors:  Oscar A Marcos-Contreras; Colin F Greineder; Raisa Yu Kiseleva; Hamideh Parhiz; Landis R Walsh; Viviana Zuluaga-Ramirez; Jacob W Myerson; Elizabeth D Hood; Carlos H Villa; Istvan Tombacz; Norbert Pardi; Alecia Seliga; Barbara L Mui; Ying K Tam; Patrick M Glassman; Vladimir V Shuvaev; Jia Nong; Jacob S Brenner; Makan Khoshnejad; Tom Madden; Drew Weissmann; Yuri Persidsky; Vladimir R Muzykantov
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-31       Impact factor: 11.205

2.  Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain.

Authors:  Oscar A Marcos-Contreras; Jacob S Brenner; Raisa Y Kiseleva; Viviana Zuluaga-Ramirez; Colin F Greineder; Carlos H Villa; Elizabeth D Hood; Jacob W Myerson; Silvia Muro; Yuri Persidsky; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2019-03-11       Impact factor: 9.776

3.  A Robust Method for Assaying the Immunoreactive Fraction in Nonequilibrium Systems.

Authors:  Thibaut Denoël; Luca Pedrelli; Giuseppe Pantaleo; John O Prior
Journal:  Pharmaceuticals (Basel)       Date:  2019-12-03

4.  Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9.

Authors:  Makan Khoshnejad; Jacob S Brenner; William Motley; Hamideh Parhiz; Colin F Greineder; Carlos H Villa; Oscar A Marcos-Contreras; Andrew Tsourkas; Vladimir R Muzykantov
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.